Should I buy or sell USANA Health Sciences stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for USANA Health Sciences in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" USNA shares. View USNA analyst ratings or view top-rated stocks .

What is USANA Health Sciences' stock price target for 2024?

2 Wall Street research analysts have issued 1-year price targets for USANA Health Sciences' shares. Their USNA share price targets range from $48.00 to $48.00. On average, they anticipate the company's stock price to reach $48.00 in the next twelve months. This suggests a possible upside of 8.5% from the stock's current price. View analysts price targets for USNA or view top-rated stocks among Wall Street analysts .

How have USNA shares performed in 2024?

USANA Health Sciences' stock was trading at $53.60 on January 1st, 2024. Since then, USNA shares have decreased by 17.5% and is now trading at $44.23. View the best growth stocks for 2024 here .

Are investors shorting USANA Health Sciences?

USANA Health Sciences saw a increase in short interest in March. As of March 15th, there was short interest totaling 255,100 shares, an increase of 49.4% from the February 29th total of 170,700 shares. Based on an average trading volume of 76,200 shares, the short-interest ratio is currently 3.3 days. Currently, 2.3% of the shares of the stock are short sold. View USANA Health Sciences' Short Interest .

When is USANA Health Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024. View our USNA earnings forecast .

How can I listen to USANA Health Sciences' earnings call?

USANA Health Sciences will be holding an earnings conference call on Wednesday, May 1st at 11:00 AM Eastern. Interested parties can register for or listen to the call using this link .

How were USANA Health Sciences' earnings last quarter?

USANA Health Sciences, Inc. (NYSE:USNA) announced its quarterly earnings results on Tuesday, February, 6th. The company reported $0.87 EPS for the quarter, topping analysts' consensus estimates of $0.52 by $0.35. The business had revenue of $221.08 million for the quarter, compared to analyst estimates of $206.70 million. USANA Health Sciences had a net margin of 6.93% and a trailing twelve-month return on equity of 13.49%.

What ETFs hold USANA Health Sciences' stock?

ETFs with the largest weight of USANA Health Sciences (NYSE:USNA) stock in their portfolio include Invesco S&P SmallCap Consumer Staples ETF (PSCC) and Global X Health & Wellness ETF (BFIT) .

What guidance has USANA Health Sciences issued on next quarter's earnings?

USANA Health Sciences issued an update on its FY 2024 earnings guidance on Tuesday, February, 6th. The company provided earnings per share (EPS) guidance of 2.400-3.000 for the period, compared to the consensus earnings per share estimate of 2.940. The company issued revenue guidance of $850.0 million-$920.0 million, compared to the consensus revenue estimate of $912.3 million.

What is Kevin Guest's approval rating as USANA Health Sciences' CEO?

68 employees have rated USANA Health Sciences Chief Executive Officer Kevin Guest on Glassdoor.com . Kevin Guest has an approval rating of 99% among the company's employees. This puts Kevin Guest in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of USANA Health Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other USANA Health Sciences investors own include International Business Machines (IBM) , Gilead Sciences (GILD) , NVIDIA (NVDA) , AT&T (T) , BioMarin Pharmaceutical (BMRN) , Vertex Pharmaceuticals (VRTX) , AbbVie (ABBV) , Walt Disney (DIS) , Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ) .

Who are USANA Health Sciences' major shareholders?

USANA Health Sciences' stock is owned by many different institutional and retail investors. Top institutional investors include West Coast Financial LLC (0.23%), Denali Advisors LLC (0.13%), First Hawaiian Bank (0.05%), DGS Capital Management LLC (0.04%), CWM LLC (0.01%) and Allspring Global Investments Holdings LLC (0.00%). Insiders that own company stock include Brent Neidig , Daniel A Macuga , David Mulham Mulham , Frederic J Winssinger , G Doug Iiekking , Gilbert A Fuller, Gilbert A Fuller , Jim Brown , John Turman Fleming , Joshua Foukas , Kevin Guest, Paul A Jones, Robert A Sinnott, Robert A Sinnott , Robert Auciaux , Walter Noot and Xia Ding. View institutional ownership trends .

How do I buy shares of USANA Health Sciences?

Shares of USNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:USNA

USANA Health Sciences (USNA) Stock Price, News & Analysis

→ Forget NVIDIA, buy this $2 AI stock now… (From Behind the Markets) (Ad)

Free USNA Stock Alerts

$44.13

+0.66 (+1.52%)

(As of 04:10 PM ET)

Compare

Today's Range: $43.34
▼
$44.31
50-Day Range: $43.01
▼
$52.36
52-Week Range: $42.59
▼
$69.60

Volume: 85,577 shs
Average Volume: 80,709 shs
Market Capitalization: $849.06 million

P/E Ratio: 13.37
Dividend Yield: N/A
Price Target: $48.00

Get USANA Health Sciences alerts:

USANA Health Sciences MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 8.5% Upside
$48.00 Price Target
Short Interest: Healthy
2.21% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.03
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$1.20 M Sold Last Quarter
Proj. Earnings Growth: 14.65%
From $2.73 to $3.13 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.12 out of 5 stars

Medical Sector

214th out of 918 stocks

Medicinals & Botanicals Industry

2nd out of 8 stocks

1.3

Analyst's Opinion

Consensus Rating
USANA Health Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
USANA Health Sciences has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
2.21% of the float of USANA Health Sciences has been sold short.
Short Interest Ratio / Days to Cover
USANA Health Sciences has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in USANA Health Sciences has recently decreased by 2.39%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
USANA Health Sciences does not currently pay a dividend.
Dividend Growth
USANA Health Sciences does not have a long track record of dividend growth.

3.0

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
USANA Health Sciences has received a 27.31% net impact score from Upright. The largest positive contribution comes from its "Nutrition" impact, which is mostly driven by its "Direct selling of nutritional products through representatives", "Direct selling of dietary supplements through representatives", and "Direct selling of skincare products through representatives" products. See details.
Environmental Sustainability
The Environmental Impact score for USANA Health Sciences is -2.03.

1.3

News and Social Media Coverage

News Sentiment
USANA Health Sciences has a news sentiment score of -0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for USANA Health Sciences this week, compared to 2 articles on an average week.
MarketBeat Follows
3 people have added USANA Health Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, USANA Health Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,200,791.00 in company stock.
Percentage Held by Insiders
Only 0.33% of the stock of USANA Health Sciences is held by insiders.
Percentage Held by Institutions
54.25% of the stock of USANA Health Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for USANA Health Sciences are expected to grow by 14.65% in the coming year, from $2.73 to $3.13 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of USANA Health Sciences is 13.40, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 139.49.
Price to Earnings Ratio vs. Sector
The P/E ratio of USANA Health Sciences is 13.40, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 207.50.
Price to Earnings Growth Ratio
USANA Health Sciences has a PEG Ratio of 1.32. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
USANA Health Sciences has a P/B Ratio of 1.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About USANA Health Sciences Stock (NYSE:USNA)

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products through retail stores and online. The company has a research collaboration agreement with Beijing University of Chinese Medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.

USNA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

USNA Stock News Headlines

April 14, 2024 | americanbankingnews.com

USANA Health Sciences (NYSE:USNA) Reaches New 1-Year Low at $43.83

April 10, 2024 | businesswire.com

USANA Schedules First Quarter 2024 Earnings Release and Conference Call

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 9, 2024 | prnewswire.com

USANA Cements Itself as a Premier Cellular Nutrition Company in South Korea

April 8, 2024 | finance.yahoo.com

USANA Health Sciences, Inc. (NYSE:USNA) has caught the attention of institutional investors who hold a sizeable 49% stake

April 2, 2024 | finance.yahoo.com

Kevin Guest Says This Spring Cultivate a Growth Mindset: The Essential Soft Skill for Business Success in 2024

March 25, 2024 | finance.yahoo.com

Some Investors May Be Worried About USANA Health Sciences' (NYSE:USNA) Returns On Capital

March 16, 2024 | finance.yahoo.com

USNA Apr 2024 45.000 put

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 11, 2024 | finance.yahoo.com

Usana Health Sciences Inc (USNA) Executive Chairman of the Board Kevin Guest Sells 11,011 Shares

March 6, 2024 | finance.yahoo.com

Usana Health Sciences Inc (USNA) Chief Scientific Officer Robert Sinnott Sells Company Shares

March 4, 2024 | finance.yahoo.com

Usana Health Sciences Inc's Chief Legal Officer Joshua Foukas Sells Company Shares

February 28, 2024 | prnewswire.com

Kevin Guest Says Leap Forward on Leap Day

February 22, 2024 | prnewswire.com

USANA Sustainability and DEI Executive Director Awarded in Utah

February 14, 2024 | finance.yahoo.com

Jim Simons Adjusts Position in Usana Health Sciences Inc

February 8, 2024 | finance.yahoo.com

USANA Health Sciences Full Year 2023 Earnings: EPS Beats Expectations

February 8, 2024 | finance.yahoo.com

USANA Health Sciences, Inc. (NYSE:USNA) Q4 2023 Earnings Call Transcript

February 7, 2024 | finance.yahoo.com

USANA Health Sciences (USNA) Q4 Earnings and Revenues Beat Estimates

February 6, 2024 | finance.yahoo.com

Usana Health Sciences Inc (USNA) Reports Mixed Fiscal Year 2023 Results

February 6, 2024 | markets.businessinsider.com

USANA Health Sciences Q4 Income Climbs, Beats estimates

February 6, 2024 | finance.yahoo.com

USANA (NYSE:USNA) Q4 Sales Beat Estimates

February 1, 2024 | finance.yahoo.com

Kevin Guest Calls on All to Connect during February Month of Friendship

February 1, 2024 | finance.yahoo.com

Euromonitor International names USANA Malaysia and Singapore Top #1 Brand for Probiotic Supplements When Combined

January 29, 2024 | finance.yahoo.com

Unpacking Q3 Earnings: USANA (NYSE:USNA) In The Context Of Other Personal Care Stocks

January 25, 2024 | finance.yahoo.com

USANA Manufacturing Facility Receives Coveted GFSI Certification from SQF

January 23, 2024 | finance.yahoo.com

USANA to Continue Investing in Local Community after Decades-Long Amphitheatre Sponsorship Ends

January 21, 2024 | finance.yahoo.com

Declining Stock and Decent Financials: Is The Market Wrong About USANA Health Sciences, Inc. (NYSE:USNA)?

See More Headlines

Receive USNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for USANA Health Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/06/2024
Today: 4/19/2024
Next Earnings (Confirmed): 4/30/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Medicinals & botanicals
Sub-Industry: Personal Products
Current Symbol: NYSE:USNA
CUSIP: 90328M10
CIK: 896264
Web: www.usana.com
Phone: (801) 954-7100
Fax: 801-954-7300
Employees: 1,800
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $48.00
High Stock Price Target: $48.00
Low Stock Price Target: $48.00
Potential Upside/Downside: +8.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): $3.30
Trailing P/E Ratio: 13.40
Forward P/E Ratio: 16.20
P/E Growth: 1.32
Net Income: $63.79 million
Net Margins: 6.93%
Pretax Margin: 11.12%
Return on Equity: 13.49%
Return on Assets: 10.45%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.52
Quick Ratio: 3.00

Sales & Book Value

Annual Sales: $921.01 million
Price / Sales: 0.92
Cash Flow: $4.53 per share
Price / Cash Flow: 9.77
Book Value: $25.99 per share
Price / Book: 1.70

Miscellaneous

Outstanding Shares: 19,240,000
Free Float: 19,178,000
Market Cap: $850.99 million
Optionable: Optionable
Beta: 0.91

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Mr. Kevin G. Guest (Age 61)
Executive Chairman
Comp: $1.08M
Mr. Jim Brown (Age 55)
CEO & President
Comp: $910.73k
Mr. G. Douglas Hekking (Age 54)
Chief Financial Officer
Comp: $638.34k
Mr. Walter Noot (Age 58)
Chief Operating Officer
Comp: $623.77k
Mr. P. Joshua Foukas (Age 48)
Chief Legal Officer, General Counsel & Corporate Secretary
Comp: $561.28k
Mr. Daniel A. Macuga Jr. (Age 54)
Chief Communications & Marketing Officer
Comp: $563k
Dr. Myron W. Wentz (Age 83)
Founder & Chairman Emeritus
Dr. John Cuomo
Executive Director of Product Development & Technology
Dr. Robert A. Sinnott M.N.S. (Age 59)
Ph.D., Chief Scientific Officer
Mr. Patrique Richards
Executive Director of Investor Relations & Business Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

USNA Stock Analysis - Frequently Asked Questions

Should I buy or sell USANA Health Sciences stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for USANA Health Sciences in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" USNA shares.
View USNA analyst ratings or view top-rated stocks.
What is USANA Health Sciences' stock price target for 2024?: 2 Wall Street research analysts have issued 1-year price targets for USANA Health Sciences' shares. Their USNA share price targets range from $48.00 to $48.00. On average, they anticipate the company's stock price to reach $48.00 in the next twelve months. This suggests a possible upside of 8.5% from the stock's current price.
View analysts price targets for USNA or view top-rated stocks among Wall Street analysts.
How have USNA shares performed in 2024?: USANA Health Sciences' stock was trading at $53.60 on January 1st, 2024. Since then, USNA shares have decreased by 17.5% and is now trading at $44.23.
View the best growth stocks for 2024 here.
Are investors shorting USANA Health Sciences?: USANA Health Sciences saw a increase in short interest in March. As of March 15th, there was short interest totaling 255,100 shares, an increase of 49.4% from the February 29th total of 170,700 shares. Based on an average trading volume of 76,200 shares, the short-interest ratio is currently 3.3 days. Currently, 2.3% of the shares of the stock are short sold.
View USANA Health Sciences' Short Interest.
When is USANA Health Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024.
View our USNA earnings forecast.
How can I listen to USANA Health Sciences' earnings call?: USANA Health Sciences will be holding an earnings conference call on Wednesday, May 1st at 11:00 AM Eastern. Interested parties can register for or listen to the call using this link.
How were USANA Health Sciences' earnings last quarter?: USANA Health Sciences, Inc. (NYSE:USNA) announced its quarterly earnings results on Tuesday, February, 6th. The company reported $0.87 EPS for the quarter, topping analysts' consensus estimates of $0.52 by $0.35. The business had revenue of $221.08 million for the quarter, compared to analyst estimates of $206.70 million. USANA Health Sciences had a net margin of 6.93% and a trailing twelve-month return on equity of 13.49%.

What ETFs hold USANA Health Sciences' stock?: ETFs with the largest weight of USANA Health Sciences (NYSE:USNA) stock in their portfolio include Invesco S&P SmallCap Consumer Staples ETF (PSCC) and Global X Health & Wellness ETF (BFIT).
What guidance has USANA Health Sciences issued on next quarter's earnings?: USANA Health Sciences issued an update on its FY 2024 earnings guidance on Tuesday, February, 6th. The company provided earnings per share (EPS) guidance of 2.400-3.000 for the period, compared to the consensus earnings per share estimate of 2.940. The company issued revenue guidance of $850.0 million-$920.0 million, compared to the consensus revenue estimate of $912.3 million.
What is Kevin Guest's approval rating as USANA Health Sciences' CEO?: 68 employees have rated USANA Health Sciences Chief Executive Officer Kevin Guest on Glassdoor.com. Kevin Guest has an approval rating of 99% among the company's employees. This puts Kevin Guest in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of USANA Health Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other USANA Health Sciences investors own include International Business Machines (IBM), Gilead Sciences (GILD), NVIDIA (NVDA), AT&T (T), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Walt Disney (DIS), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).
Who are USANA Health Sciences' major shareholders?: USANA Health Sciences' stock is owned by many different institutional and retail investors. Top institutional investors include West Coast Financial LLC (0.23%), Denali Advisors LLC (0.13%), First Hawaiian Bank (0.05%), DGS Capital Management LLC (0.04%), CWM LLC (0.01%) and Allspring Global Investments Holdings LLC (0.00%). Insiders that own company stock include Brent Neidig, Daniel A Macuga, David Mulham Mulham, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Gilbert A Fuller, Jim Brown, John Turman Fleming, Joshua Foukas, Kevin Guest, Paul A Jones, Robert A Sinnott, Robert A Sinnott, Robert Auciaux, Walter Noot and Xia Ding.
View institutional ownership trends.
How do I buy shares of USANA Health Sciences?: Shares of USNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:USNA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial